TransMedics Group, Inc. faces significant challenges due to aircraft maintenance issues and rising aviation costs, leading to a 42% stock price drop and a HOLD rating. Revenue shortfall is attribut...

On September 30, 2024, FMR LLC (Trades, Portfolio) executed a significant transaction involving the sale of 2,281,896 shares of TransMedics Group Inc (TMDX, Financial), a leader in advanced organ t...

TransMedics is revolutionizing organ transportation with its FDA-approved Organ Care System, improving organ functionality during transport. Significant investments in logistics, including owning a...

TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Recently, U.S. stock markets have been more volatile than usual. TransMedics stock has surged thanks to revenue that has more than doubled this year.

TransMedics Group, Inc. reported 117.9% YoY revenue growth in Q2 2024 and raised full-year guidance significantly, showcasing strong financial performance. Acquisition of Summit Aviation and buildi...

TransMedics Group had a remarkable second quarter, beating revenue estimates and raising guidance. The company's National Organ Care Systems Program is driving growth, with liver revenues up 2.4x a...

The headline numbers for TransMedics (TMDX) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street es...

TransMedics Group, Inc. (TMDX) Q2 2024 Earnings Call Transcript

ANDOVER, Mass. , May 17, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with en...

Does TransMedics (TMDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks.com users have recently been watching TransMedics (TMDX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

TransMedics (TMDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

TransMedics (TMDX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

TransMedics Group, Inc. (NASDAQ:TMDX ) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - Presiden...